Eli Lilly Covid Antibody Trial Paused Due to Safety Concerns
5 years ago 1 min read
Eli Lilly & Co. said enrollment of participants in a clinical trial of its antibody treatment for Covid-19 has been paused due to a potential safety concern, pushing down the company’s shares.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push